Description: AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer's disease, sleep disorders, depression, traumatic brain injuries, and Parkinson's disease, which is in phase I clinical trial; ACD857, ACD679, and ACD680 that are in preclinical trial for the treatment of Alzheimer's disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain indications; and ACD137, negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications. AlzeCure Pharma AB (publ) was founded in 2012 and is based in Huddinge, Sweden.
Home Page: www.alzecurepharma.se
HAelsovAegen 7
Huddinge,
141 57
Sweden
Phone:
46 7 63 16 24 77
Officers
| Name | Title |
|---|---|
| Mr. Martin Jönsson | Chief Executive Officer |
| Ms. Birgitta Lundvik | Chief Financial Officer |
| Mr. Johan Sandin | Chief Scientific Officer |
| Dr. Marta Segerdahl Storck M.D., Ph.D. | Chief Medical Officer & Head of Development |
| Mr. Pontus Forsell | Head of Research & Discovery |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.7772 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 11 |